サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795323

硫酸キニジンの世界市場

Quinidine Sulfate

出版日
ページ情報
英文 175 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
硫酸キニジンの世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

硫酸キニジンの世界市場は2030年までに13億米ドルに達する

2024年に11億米ドルと推定される硫酸キニジンの世界市場は、分析期間2024-2030年にCAGR 2.9％で成長し、2030年には13億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるマラリアは、CAGR 2.2％を記録し、分析期間終了時には7億3,870万米ドルに達すると予測されます。不整脈セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は3億380万米ドルと推定、中国はCAGR 5.4％で成長予測

米国の硫酸キニジン市場は、2024年に3億380万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.4%として、2030年までに2億5,650万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.2%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の硫酸キニジン市場- 主要動向と促進要因のまとめ

最新の心血管治療において硫酸キニジンが果たす役割とは？

硫酸キニジンは、主に心房性不整脈および心室性不整脈の治療に使用される重要な抗不整脈薬として、長い間その地位を占めてきました。キニジンはキナノキの樹皮に由来し、心臓の電気伝導を遅らせてリズムを安定させ、頻脈性不整脈の再発を予防します。臨床現場では、生物学的利用能と薬物動態が優れているため、硫酸塩の形で経口投与するのが最も一般的です。より新しい抗不整脈薬の出現によりその使用は減少しているが、ニッチな用途、特に現代の代替薬に不耐性や抵抗性を示す患者には依然として不可欠な薬剤です。また、ブルガダ症候群やある種のQT短縮症候群に対する有効性から、その使用が見直されています。

ヘルスケア担当者は、特に心房細動患者の長期リズム維持療法のために、慎重に漸増投与して硫酸キニジンを処方することが多いです。また、他のキニーネ誘導体が効かない耐性マラリア原虫の治療にも使用されます。このような二重の使用法がWHOの必須医薬品モデルリストに収載された背景には、循環器疾患と熱帯病の薬物療法におけるキニーネの継続的な重要性が示されています。現在の医学文献では、精密ベースの治療プロトコールが発展しつつある小児心臓病や稀な遺伝性不整脈におけるその価値が強調されています。

市場妥当性を支える主な用途と最終用途動向は？

世界の硫酸キニジン市場は、主に病院、心臓専門医療センター、研究機関での用途によって牽引されています。この化合物は経口剤と注射剤で供給されており、外来患者向けでは経口硫酸塩製剤が主流です。不整脈管理、特に複数の合併症を持つ高齢者患者への重点が高まる中、キニジンをベースとしたレジメンへの需要は引き続き重要です。さらに、心房細動や先天性症候群に対する最適な薬物経路を特定するための薬理ゲノミクスの利用が増加していることから、旧来の抗不整脈薬、特にキニジンのような安全性プロファイルが十分に証明された抗不整脈薬への関心が活性化しています。

最終用途のダイナミクスという点では、この化合物は学術研究や薬剤のリポジショニングイニシアチブにおいて新たな需要を目の当たりにしています。ALS（筋萎縮性側索硬化症）やてんかんのような神経筋疾患では、ナトリウムチャネルを独自の方法で調節する硫酸キニジンの再配置が調査されています。また、特に馬の心臓疾患への応用が検討されています。さらに、低開発地域の薬剤耐性マラリア株をターゲットとした世界・ヘルス・イニシアチブは、公衆衛生チャネルを通じた政府調達を促進しており、硫酸キニジン市場に、一般に認識されているよりも幅広い地理的・治療的範囲を与えています。

規制と医薬品サプライチェーンは市場拡大をどのように形成しているか？

硫酸キニジンを管理する規制状況は、厳しい品質、用量、ファーマコビジランス基準によって特徴付けられています。北米や欧州では、その使用は厳しく管理されており、QT延長やTorsades de Pointesのリスクがあるため、しばしば心臓モニタリングが必要とされます。しかし、このような規制によって、特に先天性不整脈の発生率が高い地域や、代替療法が経済的に実行不可能な地域で、その有用性が減殺されることはないです。インド、中国、東欧のジェネリック医薬品メーカーが世界サプライチェーンに貢献し、新興市場で硫酸キニジンを入手しやすくするとともに、国際援助や保健プログラムを支援しています。

サプライチェーンの観点からは、限られた原薬（API）サプライヤーに依存しているため、市場は定期的な課題に直面しています。天然資源からのキニジンの抽出は複雑で、合成生産は依然としてコスト集約的です。こうした要因が近年の価格変動の一因となっています。このような状況にもかかわらず、ブラジル、インドネシア、南アフリカなどの国々では、政府の支援による必須医薬品プログラムや希少疾患償還の枠組みへの組み入れにより、流通チャネルが活発に維持されています。また、NGOと製薬会社との提携により、商業化は進んでいないもの、臨床依存度の高い地域市場にも硫酸キニジンの足跡が広がっています。

硫酸キニジン市場の成長の原動力は？

硫酸キニジン市場の成長の原動力はいくつかの要因によりますが、特に遺伝的に誘発される不整脈や稀な心臓症候群の管理に対する臨床的関心が再び高まっていることが挙げられます。特に高齢化社会における心房細動の世界の増加は、従来のβ遮断薬やカルシウム拮抗薬以外の多様な薬理学的選択肢に対する並行した需要を生み出しています。また、個別化医療が再び重視されるようになったことで、硫酸キニジンは個々の患者プロファイルや有効性を示す遺伝子マーカーに基づいて選択的に再採用されるようになっています。

特に、ナトリウムチャネルに関連する神経疾患の治療における適応外の可能性が研究者により明らかになるにつれて、薬剤再利用の取り組みが市場の成長をさらに後押ししています。さらに、特定の地域では薬剤耐性マラリアとの闘いにおける役割も市場を支えており、そこでは依然として有効かつ不可欠なセカンドライン治療薬となっています。さらに、特定の公的ヘルスケアシステムにおいて、新しい抗不整脈薬よりも硫酸キニジンの方がコスト面で有利であることから、その使用は引き続き強化されています。学術試験や機関研究が使用事例の拡大を模索していることから、硫酸キニジンの世界市場は今後10年間、治療分野や地域セグメントを問わず安定した成長を維持すると予想されます。

セグメント

疾患タイプ（マラリア、不整脈、その他の疾患）

調査対象企業の例

  • ALLURE REMEDIES PVT. LTD.
  • Aurobindo Pharma
  • Bennet Pharmaceuticals Ltd
  • Biophore India Pharmaceuticals Pvt. Ltd
  • Buchler GmbH
  • Cipla Ltd
  • Dr.Reddy's Laboratories Ltd
  • Intas Pharmaceuticals
  • Ipca Laboratories Ltd
  • Lark Laboratories India Ltd
  • Merck & Co., Inc.
  • Merck KGaA
  • Mylan N.V.（Viatrus/Mylan）
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Skymax Laboratories
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37853

Global Quinidine Sulfate Market to Reach US$1.3 Billion by 2030

The global market for Quinidine Sulfate estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Malaria, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$738.7 Million by the end of the analysis period. Growth in the Arrhythmias segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$303.8 Million While China is Forecast to Grow at 5.4% CAGR

The Quinidine Sulfate market in the U.S. is estimated at US$303.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$256.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Quinidine Sulfate Market - Key Trends & Drivers Summarized

What Role Does Quinidine Sulfate Play in Modern Cardiovascular Therapies?

Quinidine sulfate has long held its position as a key antiarrhythmic agent, primarily used in the treatment of atrial and ventricular arrhythmias. Derived from the cinchona bark, quinidine works by slowing electrical conduction in the heart, stabilizing rhythm, and preventing recurrent episodes of tachyarrhythmia. In clinical settings, it is most commonly administered orally in sulfate form due to its superior bioavailability and pharmacokinetics. Although its use has declined with the advent of newer antiarrhythmic drugs, it remains an essential agent for niche applications, particularly in patients who demonstrate intolerance or resistance to contemporary alternatives. Its use is also being revisited due to its efficacy in treating Brugada syndrome and certain forms of short QT syndrome.

Healthcare practitioners often prescribe quinidine sulfate in carefully titrated doses, especially for long-term rhythm maintenance therapy in atrial fibrillation patients. The drug is also indicated in the management of malaria caused by Plasmodium falciparum in resistant cases, where other quinine derivatives fail. This duality of use supports its inclusion on the WHO Model List of Essential Medicines, indicating its continued relevance in both cardiovascular and tropical disease pharmacotherapy. Current medical literature highlights its value in pediatric cardiology and rare genetic arrhythmias where precision-based treatment protocols are evolving.

What Are the Key Applications and End-Use Trends Supporting Its Market Relevance?

The global quinidine sulfate market is majorly driven by applications in hospitals, specialty cardiac care centers, and research institutions. The compound is supplied in oral and injectable formats, with the oral sulfate form dominating the outpatient segment. With increasing focus on arrhythmia management, particularly in geriatric patients with multiple comorbidities, the demand for quinidine-based regimens remains relevant. Furthermore, the rising use of pharmacogenomics to identify optimal drug pathways for atrial fibrillation and congenital syndromes has revitalized interest in older antiarrhythmic compounds, especially those with a well-documented safety profile like quinidine.

In terms of end-use dynamics, the compound is witnessing renewed demand in academic research and drug repositioning initiatives. Research efforts are examining the repositioning of quinidine sulfate for neuromuscular diseases such as ALS (Amyotrophic Lateral Sclerosis) and epilepsy, where it modulates sodium channels in unique ways. Veterinary applications are also under investigation, particularly for equine cardiac conditions. Additionally, global health initiatives targeting drug-resistant malaria strains in underdeveloped regions are driving government procurements through public health channels, giving the quinidine sulfate market a broader geographical and therapeutic reach than typically acknowledged.

How Are Regulations and Drug Supply Chains Shaping Market Expansion?

The regulatory landscape governing quinidine sulfate is characterized by stringent quality, dosage, and pharmacovigilance standards. In North America and Europe, its use is tightly controlled, often requiring cardiac monitoring due to the risk of QT prolongation and torsades de pointes. However, these regulations have not dampened its utility, particularly in regions with high incidence of congenital arrhythmias or where alternative therapies are economically unfeasible. Generic manufacturers in India, China, and Eastern Europe have contributed to the global supply chain, making quinidine sulfate accessible in emerging markets while also supporting international aid and health programs.

From a supply chain perspective, the market faces periodic challenges due to reliance on limited active pharmaceutical ingredient (API) suppliers. The extraction of quinidine from natural sources is complex, and synthetic production remains cost-intensive. These factors have contributed to price volatility in recent years. Despite this, government-backed essential medicine programs and inclusion in rare disease reimbursement frameworks in countries like Brazil, Indonesia, and South Africa are keeping the distribution channels active. Partnerships between NGOs and pharmaceutical suppliers are also expanding the footprint of quinidine sulfate into less commercialized, yet clinically dependent, regional markets.

What Is Driving the Growth of the Quinidine Sulfate Market?

The growth in the quinidine sulfate market is driven by several factors, most notably the resurgence in clinical interest for managing genetically triggered arrhythmias and rare cardiac syndromes. Rising incidences of atrial fibrillation globally, especially among aging populations, have created a parallel demand for diverse pharmacologic options beyond contemporary beta-blockers and calcium channel blockers. The renewed emphasis on personalized medicine is also leading to selective re-adoption of quinidine sulfate based on individual patient profiles and genetic markers that favor its efficacy.

Drug repurposing initiatives further support market growth, especially as researchers uncover its off-label potential in treating sodium-channel related neurological conditions. The market is additionally supported by its role in combating drug-resistant malaria in specific geographies, where it remains an effective and essential second-line treatment. Moreover, the cost advantage of quinidine sulfate over newer antiarrhythmic agents in certain public healthcare systems continues to reinforce its usage. With academic trials and institutional research exploring expanded use cases, the global market for quinidine sulfate is expected to maintain steady growth across therapeutic and geographic segments over the coming decade.

SCOPE OF STUDY:

The report analyzes the Quinidine Sulfate market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Malaria, Arrhythmias, Other Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • ALLURE REMEDIES PVT. LTD.
  • Aurobindo Pharma
  • Bennet Pharmaceuticals Ltd
  • Biophore India Pharmaceuticals Pvt. Ltd
  • Buchler GmbH
  • Cipla Ltd
  • Dr.?Reddy's Laboratories Ltd
  • Intas Pharmaceuticals
  • Ipca Laboratories Ltd
  • Lark Laboratories India Ltd
  • Merck & Co., Inc.
  • Merck KGaA
  • Mylan N.V. (Viatrus/Mylan)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Skymax Laboratories
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Quinidine Sulfate - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Atrial Fibrillation and Cardiac Arrhythmias Drives Demand for Antiarrhythmic Drugs
    • Innovation in Extended-Release Formulations Strengthens Treatment Adherence
    • Growth in Rare Disease Treatment Protocols Throws the Spotlight on Quinidine's Broader Applications
    • Regulatory Reapprovals for Repurposed Molecules Promote Quinidine Use in Orphan Indications
    • Development of Digital Cardiology Platforms Enhances Drug Monitoring Capabilities
    • Increasing Availability of Compounded Quinidine Formulations Boosts Hospital-Based Prescriptions
    • Partnerships With Cardiologists Strengthen Protocol-Based Dosing Adoption
    • Growing Research on Genetic Markers in Drug Metabolism Supports Personalized Dosage Regimens
    • Focus on Drug-Drug Interaction Risk Management Promotes Safer Combination Therapies
    • Expansion of Quinidine Application in Neurological Disorders Broadens Therapeutic Potential
    • Regulatory Guidance on Narrow Therapeutic Index Drugs Drives Monitoring Standards
    • Innovation in Microdose and Pediatric Formulations Supports Specialty Market Penetration
    • Rising Emphasis on Labeling Accuracy and GMP Compliance Fuels Manufacturing Modernization
    • Collaboration With Pharmacovigilance Networks Improves Long-Term Safety Profiling
    • Growth in Availability of Online Pharmacies and Specialty Drug Distributors Enhances Market Reach
    • Entry Into Global Licensing Agreements Strengthens Regional Access Strategies
    • Increasing Interest in Drug Repositioning Accelerates Investment in Quinidine Research
    • Support for Cardiology Clinics and Hospital Networks Boosts Direct Engagement
    • Emergence of Drug Supply Shortage Mitigation Programs Promotes Production Scalability
    • Expansion of Clinical Trial Evidence Base Elevates Prescriber Confidence in Quinidine Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Quinidine Sulfate Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Arrhythmias by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • JAPAN
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CHINA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • EUROPE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • FRANCE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • GERMANY
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • INDIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AFRICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030

IV. COMPETITION